Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Center-Specific Modeling Predicts Cancer Trial Accrual More Accurately Than Investigators and Random Effects Modeling at 16 Cancer Centers.

Tate WR, Abraham I, Cranmer LD.

JCO Clin Cancer Inform. 2019 Jun;3:1-12. doi: 10.1200/CCI.19.00005.

2.

Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.

Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM.

Cancer Immunol Res. 2019 Jun 6. doi: 10.1158/2326-6066.CIR-18-0940. [Epub ahead of print]

PMID:
31171504
3.

Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date.

Cranmer LD.

Onco Targets Ther. 2019 Mar 18;12:2047-2062. doi: 10.2147/OTT.S145539. eCollection 2019. Review.

4.

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.

Almutairi AR, Alkhatib NS, Oh M, Curiel-Lewandrowski C, Babiker HM, Cranmer LD, McBride A, Abraham I.

JAMA Dermatol. 2019 Jan 1;155(1):22-28. doi: 10.1001/jamadermatol.2018.3958.

PMID:
30477000
5.

Response to PD1 inhibition in conventional chondrosarcoma.

Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM, Cranmer LD.

J Immunother Cancer. 2018 Sep 25;6(1):94. doi: 10.1186/s40425-018-0413-z.

6.

Propranolol for the treatment of vascular sarcomas.

Wagner MJ, Cranmer LD, Loggers ET, Pollack SM.

J Exp Pharmacol. 2018 Sep 6;10:51-58. doi: 10.2147/JEP.S146211. eCollection 2018. Review.

7.

Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.

Zager JS, Gastman BR, Leachman S, Gonzalez RC, Fleming MD, Ferris LK, Ho J, Miller AR, Cook RW, Covington KR, Meldi-Plasseraud K, Middlebrook B, Kaminester LH, Greisinger A, Estrada SI, Pariser DM, Cranmer LD, Messina JL, Vetto JT, Wayne JD, Delman KA, Lawson DH, Gerami P.

BMC Cancer. 2018 Feb 5;18(1):130. doi: 10.1186/s12885-018-4016-3.

8.

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, Liu S, Hamid O.

Melanoma Res. 2017 Dec;27(6):585-590. doi: 10.1097/CMR.0000000000000398.

PMID:
29076950
9.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.

Eur J Cancer. 2017 Nov;86:37-45. doi: 10.1016/j.ejca.2017.07.022.

PMID:
28961465
10.

16S rRNA gene sequencing on a benchtop sequencer: accuracy for identification of clinically important bacteria.

Watts GS, Youens-Clark K, Slepian MJ, Wolk DM, Oshiro MM, Metzger GS, Dhingra D, Cranmer LD, Hurwitz BL.

J Appl Microbiol. 2017 Dec;123(6):1584-1596. doi: 10.1111/jam.13590. Epub 2017 Nov 7.

11.

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.

Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK.

Melanoma Manag. 2017 Mar;4(1):13-37. doi: 10.2217/mmt-2016-0022. Epub 2017 Mar 1. Review.

12.

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P.

Lancet Oncol. 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017 Jun 23. Erratum in: Lancet Oncol. 2018 Feb;19(2):e78.

PMID:
28651927
13.

T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.

Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL.

Cancer. 2017 Sep 1;123(17):3291-3304. doi: 10.1002/cncr.30726. Epub 2017 May 2.

14.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.

Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S.

Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.

15.

Pazopanib in the management of advanced soft tissue sarcomas.

Cranmer LD, Loggers ET, Pollack SM.

Ther Clin Risk Manag. 2016 Jun 9;12:941-55. doi: 10.2147/TCRM.S84792. eCollection 2016. Review.

16.

Targeting gastrointestinal stromal tumors: the role of regorafenib.

Schroeder B, Li Z, Cranmer LD, Jones RL, Pollack SM.

Onco Targets Ther. 2016 May 20;9:3009-16. doi: 10.2147/OTT.S104081. eCollection 2016. Review.

17.
18.

Quantitative histopathology identifies patients with thin melanomas who are at risk for metastases.

Glazer ES, Bartels PH, Lian F, Kha ST, Morgan SS, da Silva VD, Yozwiak ML, Bartels HG, Cranmer LD, de Oliveira JK, Alberts DS, Warneke JA, Krouse RS.

Melanoma Res. 2016 Jun;26(3):261-6. doi: 10.1097/CMR.0000000000000236.

PMID:
26795273
19.

Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.

Sarantopoulos J, Mita MM, Birrer MJ, Cranmer LD, Campos LT, Zhang X, Bristow P, Kaito H, Strout V, Camacho LH.

Target Oncol. 2016 Jun;11(3):317-27. doi: 10.1007/s11523-015-0394-5.

PMID:
26507836
20.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.

Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23.

PMID:
26115796
21.
22.

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN.

J Clin Oncol. 2014 Oct 10;32(29):3299-306. doi: 10.1200/JCO.2013.54.3660. Epub 2014 Sep 2.

23.

Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas.

Morgan SS, Nagle RB, Cranmer LD.

Clin Sarcoma Res. 2014 Jan 31;4(1):2. doi: 10.1186/2045-3329-4-2.

24.

Ipilimumab granulomatous interstitial nephritis.

Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD.

Am J Ther. 2015 May-Jun;22(3):e84-7. doi: 10.1097/MJT.0b013e3182a32ddc.

PMID:
24067875
25.

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY.

J Clin Oncol. 2013 Jul 1;31(19):2485-92. doi: 10.1200/JCO.2012.45.5766. Epub 2013 May 28.

PMID:
23715582
26.

Pleomorphic rhabdomyosarcoma in a patient with hereditary nonpolyposis colorectal cancer.

Cranmer LD, Chen CC, Morgan S, Martino G, Ray J.

J Clin Oncol. 2013 Mar 1;31(7):e108-10. doi: 10.1200/JCO.2012.43.4910. Epub 2013 Jan 14. No abstract available.

PMID:
23319697
27.

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

Jeter JM, Cranmer LD, Hersh EM.

Clin Med Insights Oncol. 2012;6:275-86. doi: 10.4137/CMO.S7245. Epub 2012 Jul 30.

28.

Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma.

Cruz-Muñoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O'Connor-McCourt MD, Kerbel RS.

Cancer Res. 2012 Oct 1;72(19):4909-19. doi: 10.1158/0008-5472.CAN-12-2194. Epub 2012 Aug 3.

29.

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1487-98. doi: 10.1007/s00280-012-1852-8. Epub 2012 Mar 2.

30.

Radiation-induced sarcoma of the breast: a systematic review.

Sheth GR, Cranmer LD, Smith BD, Grasso-Lebeau L, Lang JE.

Oncologist. 2012;17(3):405-18. doi: 10.1634/theoncologist.2011-0282. Epub 2012 Feb 14.

31.

A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.

Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A.

J Immunother. 2011 Sep;34(7):556-67. doi: 10.1097/CJI.0b013e3182280db1.

32.

Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future.

Morgan SS, Cranmer LD.

Curr Oncol Rep. 2011 Aug;13(4):331-49. doi: 10.1007/s11912-011-0182-z.

PMID:
21633784
33.

A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Ganjoo KN, Cranmer LD, Butrynski JE, Rushing D, Adkins D, Okuno SH, Lorente G, Kroll S, Langmuir VK, Chawla SP.

Oncology. 2011;80(1-2):50-6. doi: 10.1159/000327739. Epub 2011 May 31.

PMID:
21625179
34.

Treatment of unresectable and metastatic cutaneous squamous cell carcinoma.

Cranmer LD, Engelhardt C, Morgan SS.

Oncologist. 2010;15(12):1320-8. doi: 10.1634/theoncologist.2009-0210. Epub 2010 Dec 8.

35.

Melanoma's radioresistant reputation challenged.

Cranmer LD.

Oncology (Williston Park). 2010 Jun;24(7):656. No abstract available.

36.

Whole-brain radiation therapy in melanoma: an open question.

Cranmer LD, Jeter JM, Morgan SS, Hersh EM, Stea B.

Lancet Oncol. 2010 Jan;11(1):13; author reply 13-4. doi: 10.1016/S1470-2045(09)70346-8. No abstract available.

PMID:
20129127
37.

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS.

Invest New Drugs. 2011 Jun;29(3):489-98. doi: 10.1007/s10637-009-9376-8. Epub 2010 Jan 16.

PMID:
20082117
38.

In-transit metastasis from melanoma presenting as lymphangiectasis: a case report.

Shekhel T, Glick RM, Cranmer LD.

Cutis. 2009 Sep;84(3):151-8.

PMID:
19842575
39.

Advanced desmoplastic small round cell tumor: near complete response with trastuzumab-based chemotherapy.

Chalasani P, Shtivelband MI, Cranmer LD.

Clin Adv Hematol Oncol. 2009 Jul;7(7):473-5. No abstract available.

PMID:
19701155
40.

The role of the CTLA4 blockade in the treatment of malignant melanoma.

Cranmer LD, Hersh E.

Cancer Invest. 2007 Oct;25(7):613-31. Review.

PMID:
18027152
41.

A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.

Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A, Weitman S, Hammond LA.

Clin Cancer Res. 2005 Nov 1;11(21):7807-16.

42.

Rodent models of brain metastasis in melanoma.

Cranmer LD, Trevor KT, Bandlamuri S, Hersh EM.

Melanoma Res. 2005 Oct;15(5):325-56. Review.

PMID:
16179861
43.

Clinical applications of dendritic cell vaccination in the treatment of cancer.

Cranmer LD, Trevor KT, Hersh EM.

Cancer Immunol Immunother. 2004 Apr;53(4):275-306. Epub 2003 Nov 26. Review.

PMID:
14648069
44.

61-year-old man with dyspnea and bilateral foot drop.

Cranmer LD, Warrington KJ, Ytterberg SR.

Mayo Clin Proc. 2002 Apr;77(4):363-6. No abstract available.

PMID:
11936933
48.

DNA immunization confers protection against murine cytomegalovirus infection.

González Armas JC, Morello CS, Cranmer LD, Spector DH.

J Virol. 1996 Nov;70(11):7921-8.

50.

Gonyauline: a novel endogenous substance shortening the period of the circadian clock of a unicellular alga.

Roenneberg T, Nakamura H, Cranmer LD 3rd, Ryan K, Kishi Y, Hastings JW.

Experientia. 1991 Jan 15;47(1):103-6.

PMID:
1999237

Supplemental Content

Loading ...
Support Center